Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E-Driven Papillary Thyroid Cancer Patients

T Pappa, S Ahmadi, E Marqusee, HL Johnson… - Clinical Cancer …, 2021 - AACR
Purpose: The extent to which routine genomic sequencing can identify relevant secondary
genomic alterations among BRAFV600E-mutant papillary thyroid carcinoma (PTC) is …
被引用次数：36 相关文章

Oncogenic mutations in PI3K/AKT/mTOR pathway effectors associate with worse prognosis in BRAFV600E-driven papillary thyroid cancer patients

T Pappa, S Ahmadi, E Marqusee… - Clinical Cancer …, 2021 - scholars.northwestern.edu
Purpose: The extent to which routine genomic sequencing can identify relevant secondary
genomic alterations among BRAF V600E mutant papillary thyroid carcinoma (PTC) is …

Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E-Driven Papillary Thyroid Cancer Patients

T Pappa, S Ahmadi, E Marqusee… - … : an official journal …, 2021 - pubmed.ncbi.nlm.nih.gov
Purpose The extent to which routine genomic sequencing can identify relevant secondary
genomic alterations among BRAF V600E-mutant papillary thyroid carcinoma (PTC) is …

Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E -Driven Papillary Thyroid Cancer Patients.

T Pappa, S Ahmadi, E Marqusee… - … Cancer Research: an …, 2021 - europepmc.org
Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse
Prognosis in BRAFV600E -Driven Papillary Thyroid Cancer Patients. - Abstract - Europe …